|
47 Companies |
|
50 Products |
|
50 Products |
|
66 Mechanisms of Action |
|
0 Trials |
|
978 News |
|
| «12...45678910111213141516» |
- Trial completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Trial completion date: Dec 2013 --> Feb 2015
- Enrollment open: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial completion date: Dec 2013 --> Feb 2015 Not yet recruiting --> Recruiting
- Enrollment open: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- heparin sodium injection / Generic mfg.
Trial withdrawal: Safety of Heparin in Patients With Septic Shock (clinicaltrials.gov) - May 18, 2014
P2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- heparin sodium injection / Generic mfg.
Enrollment change: Safety of Heparin in Patients With Septic Shock (clinicaltrials.gov) - May 18, 2014
P2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Recruiting --> Withdrawn N=100 --> 0
- Trial primary completion date: FLOVAC: FLOTRAC/VIGILEO in Acute Circulatory Failure (clinicaltrials.gov) - May 17, 2014
P=N/A, N=50, Recruiting, Sponsor: Hôpital Européen Marseille
N=100 --> 0 Trial primary completion date: Sep 2013 --> Mar 2015
- Trial completion date: FLOVAC: FLOTRAC/VIGILEO in Acute Circulatory Failure (clinicaltrials.gov) - May 17, 2014
P=N/A, N=50, Recruiting, Sponsor: Hôpital Européen Marseille
Trial primary completion date: Sep 2013 --> Mar 2015 Trial completion date: Dec 2013 --> Sep 2015
- dobutamine / Generic mfg.
Biomarker: Shockomics: Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock (clinicaltrials.gov) - May 15, 2014
P=N/A, N=115, Not yet recruiting, Sponsor: Shockomics Consortium
- || eleclazine (GS-6615) / Gilead
Trial primary completion date: TEMPO: Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (clinicaltrials.gov) - May 13, 2014
P2, N=210, Not yet recruiting, Sponsor: Gilead Sciences
Trial completion date: Dec 2013 --> Sep 2015 Trial primary completion date: Dec 2015 --> Jan 2016
- ||| eleclazine (GS-6615) / Gilead
Trial initiation date: TEMPO: Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (clinicaltrials.gov) - May 13, 2014
P2, N=210, Not yet recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2015 --> Jan 2016 Initiation date: Jun 2014 --> Jul 2014
- || eleclazine (GS-6615) / Gilead
Trial completion date: TEMPO: Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (clinicaltrials.gov) - May 13, 2014
P2, N=210, Not yet recruiting, Sponsor: Gilead Sciences
Initiation date: Jun 2014 --> Jul 2014 Trial completion date: Jan 2016 --> Feb 2016
- Trial termination: ALB-CIRINF: Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - May 11, 2014
P3, N=193, Terminated, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial completion date: Jan 2016 --> Feb 2016 Recruiting --> Terminated; decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group than in control group, without reaching significance level.
- Trial completion date: ALB-CIRINF: Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - May 11, 2014
P3, N=193, Terminated, Sponsor: Centre Hospitalier Universitaire de Besancon
Recruiting --> Terminated; decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group than in control group, without reaching significance level. Trial completion date: Sep 2011 --> Jun 2012
- Enrollment open: The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker (clinicaltrials.gov) - May 11, 2014
P=N/A, N=120, Recruiting, Sponsor: National Taiwan University Hospital
Trial completion date: Sep 2011 --> Jun 2012 Not yet recruiting --> Recruiting
- || New P3 trial: Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis (clinicaltrials.gov) - May 8, 2014
P3, N=100, Recruiting, Sponsor: Indonesia University
- Trial primary completion date: Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults (clinicaltrials.gov) - May 7, 2014
P=N/A, N=136, Recruiting, Sponsor: Denver Health and Hospital Authority
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Nov 2014
- Trial primary completion date: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
Trial primary completion date: Jun 2014 --> Nov 2014 Trial primary completion date: Mar 2014 --> May 2014
- Trial completion date: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
Trial primary completion date: Mar 2014 --> May 2014 Trial completion date: Jul 2014 --> May 2014
- Trial completion: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
Trial completion date: Jul 2014 --> May 2014 Recruiting --> Completed
- Trial withdrawal, Video: Pre Hospital Evaluation of Video Laryngoscopy (clinicaltrials.gov) - May 6, 2014
P4, N=0, Withdrawn, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change, Video: Pre Hospital Evaluation of Video Laryngoscopy (clinicaltrials.gov) - May 6, 2014
P4, N=0, Withdrawn, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Withdrawn N=262 --> 0
- Enrollment open: VENUS: Septic Gene Expression Using SeptiCyte (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=180, Recruiting, Sponsor: Intermountain Health Care, Inc.
N=262 --> 0 Not yet recruiting --> Recruiting
- Trial completion, Immune cell: Mitochondrial Function of Immune Cells in Sepsis (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=60, Completed, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- HSP Gp96 vaccine / Cure & Sure Biotech
New P1 trial: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 (clinicaltrials.gov) - Apr 23, 2014
P1, N=20, Recruiting, Sponsor: Cure&Sure Biotech Co., LTD
- HEOR, Surgery: Comparative Effectiveness of Unilateral vs. Bilateral Pulmonary Collapse in Cardiac De-airing (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=20, Recruiting, Sponsor: Lund University
- || hydrocortisone / Generic mfg.
New P3 trial: Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock (clinicaltrials.gov) - Apr 13, 2014
P3, N=240, Completed, Sponsor: Nanjing PLA General Hospital
- New P4 trial: AVATAR: Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention (clinicaltrials.gov) - Apr 13, 2014
P4, N=40, Not yet recruiting, Sponsor: University of Ottawa Heart Institute
- ||| apatorsen (OGX-427) / Achieve Life Sciences
Trial completion: Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer (clinicaltrials.gov) - Apr 9, 2014
P1, N=64, Completed, Sponsor: OncoGenex Technologies
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | midazolam hydrochloride / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis (clinicaltrials.gov) - Apr 8, 2014
P4, N=60, Not yet recruiting, Sponsor: National Taiwan University Hospital
- Trial withdrawal: CSWTSPB40: Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=0, Withdrawn, Sponsor: City Hospital No 40, Saint Petersburg, Russia
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: CSWTSPB40: Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=0, Withdrawn, Sponsor: City Hospital No 40, Saint Petersburg, Russia
Not yet recruiting --> Withdrawn N=3000 --> 0
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Apr 6, 2014
P1, N=18, Recruiting, Sponsor: New York University School of Medicine
N=3000 --> 0 Not yet recruiting --> Recruiting
- Trial completion: IL8 Monitoring and Its Correlation With 251-gene Polymorphism (clinicaltrials.gov) - Apr 5, 2014
P=N/A, N=80, Completed, Sponsor: Tanta University
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| eleclazine (GS-6615) / Gilead
New P2 trial: TEMPO: Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (clinicaltrials.gov) - Apr 2, 2014
P2, N=210, Not yet recruiting, Sponsor: Gilead Sciences
- || Enrollment closed: 4P Study: Predictive Quality With Painfree Therapies (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Medtronic Bakken Research Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- dexamethasone / Generic mfg.
Trial completion, Surgery: Dexamethasone for Cardiac Surgery Trial (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=4500, Completed, Sponsor: UMC Utrecht
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment open: Observational Study of Blood Pressure Measurements and Continuous Dialysis (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=60, Recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=40, Recruiting, Sponsor: National Jewish Health
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial initiation date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Mar 24, 2014
P2, N=150, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
Not yet recruiting --> Recruiting Initiation date: Oct 2013 --> Apr 2014
- Enrollment change: MEDUSA: Medical Education for Sepsis Source Control and Antibiotics (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=4138, Completed, Sponsor: Center for Sepsis Control and Care, Germany
Initiation date: Oct 2013 --> Apr 2014 N=2000 --> 4138
- Trial completion: MEDUSA: Medical Education for Sepsis Source Control and Antibiotics (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=4138, Completed, Sponsor: Center for Sepsis Control and Care, Germany
N=2000 --> 4138 Active, not recruiting --> Completed
- Trial completion: Efficacy of Mw Vaccine in Treatment of Severe Sepsis (clinicaltrials.gov) - Mar 18, 2014
P2/3, N=50, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: ImaCor II: Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=500, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed Not yet recruiting --> Recruiting
- New P4 trial: Effect of Different Strategies for Titrating a High MAP on Microcirculation (clinicaltrials.gov) - Mar 10, 2014
P4, N=20, Recruiting, Sponsor: Southeast University, China
- Clinical: PtcO2-FR: Fluid Responsiveness Predicted by PtcO2 in Critically Ill Patients (clinicaltrials.gov) - Mar 9, 2014
P=N/A, N=30, Recruiting, Sponsor: Southeast University, China
- Trial termination: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Not yet recruiting --> Recruiting Recruiting --> Terminated; Low recruitment rate
- Enrollment change: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Recruiting --> Terminated; Low recruitment rate N=42 --> 21
- Trial completion: Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005 (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=0, Completed, Sponsor: Bayside Health
N=42 --> 21 Recruiting --> Completed
- | New P4 trial: CLASSIC: Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (clinicaltrials.gov) - Mar 3, 2014
P4, N=150, Not yet recruiting, Sponsor: Anders Perner
- TV003 / Medigen Biotech, National Institute of Allergy and Infectious Diseases, TV005 / National Institute of Allergy and Infectious Diseases
Enrollment closed, IO biomarker: Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine (clinicaltrials.gov) - Feb 27, 2014
P1, N=112, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Active, not recruiting